Replies to post #56 on Theseus Pharmaceuticals Inc (THRX)

[surf1944]

3:18AM Theravance and GlaxoSmithKline (GSK) announce that RELVAR ELLIPTA gains approval in Japan for the treatment of asthma (THRX) 41.20 : GlaxoSmithKline (GSK) and Theravance (THRX) announce that the Japanese Ministry of Health, Labour and Welfare has approved RELVAR ELLIPTA for the treatment of bronchial asthma (in cases where concurrent use of inhaled corticosteroid and long-acting inhaled beta2 agonist is required). Relvar Ellipta is not indicated for the treatment of chronic obstructive pulmonary disease in Japan.

Under the terms of the 2002 LABA collaboration agreement, Theravance is obligated to make a milestone payment of $10 mln to GSK following MHLW approval of Relvar Ellipta in Japan.